The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Translating epigenetic therapy to the clinic: rational combinations
Ari Melnick, MD, of Weill Cornell Medical College, New York, NY, discusses the layers of complexity surrounding the epigenome in acute leukemias, which must be better understood in order to more effectively design and utilize epigenetic therapies. He highlights the importance of rational combinations, referencing research using azacitidine with an LSD1 inhibitor on an organoid culture system of primary specimens of acute myeloid leukemia (AML). This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
